Antipsychotics: History – Then and Now

The Times-News
Modern mind medicines begin to lose luster
January 27, 2009

Hundreds of years ago, people with mental illness might be burned at the stake or locked away in a dungeon. In the early 20th century, some patients with schizophrenia were lobotomized with an ice pick to blunt emotions and reduce agitation. Read the rest of this entry »

Advertisements

FDA Warnings for Abilify (Aripiprazole)

HIGHLIGHTS OF PRESCRIBING INFORMATION FOR ABILIFY (ARIPIPRAZOLE)M THE ANTI-PSCYHOTIC MEDICATION

These highlights do not include all the information needed to use ABILIFY safely and effectively. See full prescribing information for ABILIFY.

ABILIFY® (aripiprazole) Tablets

ABILIFY DISCMELT® (aripiprazole) Orally Disintegrating Tablets

ABILIFY® (aripiprazole) Oral Solution

ABILIFY® (aripiprazole) Injection FOR INTRAMUSCULAR USE ONLY

Initial U.S. Approval: 2002

BLACK BOX WARNING: Read the rest of this entry »

Celexa Side Effect Warning by FDA – Bleeding

PRECAUTIONS FOR CLEXA BY FDA:

  • General
    • Abnormal Bleeding
    • Hyponatremia
  • Information for Patients
    • Patients should be cautioned about the concomitant (concurrently; at the same time) use of Celexa and NSAIDs (a nonsteroidal anti-inflammatory drug, such as aspirin or ibuprofen), aspirin, warfarin, or other drugs that affect coagulation (blood clotting) since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of bleeding.
  • Drug Interactions
    • Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)
  • Geriatric Use
    • SSRIs and SNRIs, including Celexa, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event (see PRECAUTIONS, Hyponatremia). Read the rest of this entry »

Abilify (Aripiprazole): Lawsuit Settlement – Serious Side Effects – NOT FDA Approved in Children and Seniors

43 States have received millions of dollars in settlements from Bristol-Myers Squibb for the questionable marketing and pricing of certain prescription drugs for the poor.

Bristol-Meyers Squibb and its former subsidiary, Apothecon Inc., agreed in September to pay a total of $499 million, according to a spokeswoman for the company. The payments to the individual states, like Georgia’s Medicaid program went out in July 2008.

“The allegations were that these companies not only engaged in a pattern of kickbacks and false reporting to drive up both the sales and prices for its drugs, they also encouraged health care providers to prescribe a potent drug to both children and seniors for uses that had not been approved by the FDA,” Georgia Attorney General Thurbert Baker said in a prepared statement. “The drive to make certain that the bottom-line meets Wall Street expectations can never justify defrauding the taxpayers or putting our most vulnerable citizens at risk.” Read the rest of this entry »